-
Posted by
Two Blokes Jun 12 -
Filed in
Stock
-
6 views
IOVA Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESS Newswire / June 12, 2025 / A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically.
